20. Alan Zarendo, “Warrior Parents Fare Best in Securing Autism Services,” Los Angeles Times, December 13, 2011, Local Section; http://www.latimes.com/news/local/autism/la-me-autism-day-two-html,0,3900437.htmlstory.
21. Christine Fountain, Alix S. Winter, and Peter S. Bearman, “Six Developmental Trajectories Characterize Children with Autism,” Pediatrics 129, no. 5 (May 1, 2012): e1112–e1120.
22. V. Gibbs and others, “Brief Report: An Exploratory Study Comparing Diagnostic Outcomes for Autism Spectrum Disorders Under DSM-IV-TR with the Proposed DSM-5 Revision,” J Autism Dev Disord 42 (2012): 1750–56.
23. J. McPartland, B. Reichow, and F. R. Volkmar, “Sensitivity and specificity of proposed DSM-5 diagnostic criteria for autism spectrum disorder,” Psychiatry 51 (2012): 368–83.
24. M. Mordre, B. Groholt, A. Knudsen, E. Sponheim, A. Mykletun, and A. Myhre, “Is long term prognosis for pervasive developmental disorder not otherwise specified different from prognosis for autistic disorder? Findings from a 30 year follow up study,” Journal of Autism and Developmental Disorders (2011); doi: 10.1007/s10803-011-1319-5.
25. M. Zimmerman and others, “Is Bipolar Disorder Overdiagnosed?” J Clin Psychiatry 69 (2008): 935–40.
26. A. M. Kilbourne, E. P. Post, M. S. Bauer, and others, “Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder,” J Affect Disord 102 (2007): 145–51.
27. R. C. Kessler, W. T. Chiu, O. Demler, and E. E. Walters, “Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R),” Arch Gene Psychiatry 62, no. 6 (June 2005): 617–27.
28. C. Blanco, C. Garcia, and M. R. Liebowitz, “Epidemiology of social anxiety disorder,” in B. Bandelow and D. J. Stein, eds. Social Anxiety Disorder (New York: Marcel Dekker, 2004), 35–47.
29. Christopher Lane, PhD, Shyness: How Normal Behavior Became a Sickness (New Haven: Yale University Press, 2007).
30. U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1, 2000, to July 1, 2004 (NC-EST2004-02) Source: Population Division, U.S. Census Bureau Release Date: June 9, 2005. http://www.census.gov/popest/national/asrh.
31. Gordon Parker, “Is depression overdiagnosed? Yes.” BMJ, August 16, 2007, http://www.bmj.com/content/335/7615/328.
32. A. V. Horwitz and J. C. Wakefield, The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder (New York: Oxford University Press, 2007).
33. Lisa K. Richardson, M.App.Psy., Christopher Frueh, PhD, and Ronald Acierno, PhD, “Prevalence Estimates of Combat-Related PTSD: A Critical Review,” Aust N Z J Psychiatry 44, no. 1 (January 2010): 4–19.
34. PTSD and the Law: An Update http://www.google.com/url?q=http://www.ptsd.va.gov/professional/newsletters/research-quarterly/v22n1.pdf&sa=U&ei=RmxHUPWMLMusqQGCsYGICA&ved=0CBQQFjAA&usg=AFQjCNH0Vk0GP0YsK8HOvry7P2H-Dvrfng.
35. Helen Singer Kaplan, MD, Sexual Desire Disorders: Dysfunctional Regulation of Sexual Motivation (Levittown, PA: Brunner/Mazel, 1995).
36. Ray Moynihan, Sex, Lies, and Pharmaceuticals: How Drug Companies Plan to Profit from Female Sexual Dysfunction (Vancouver, BC: D & M Publishers, 2010).
37. A. Frances and M. First, “Paraphilia NOS, Nonconsent: Not Ready for the Courtroom,” Journal of American Academy of Psychiatry and the Law 39, no. 4 (2011): 555–61.
38. S. Sreenivasan, L. E. Weinberger, and A. Frances, “Normative and Consequential Ethics in Sexually Violent Predator Evaluations,” J Amer Psychiatry and the Law (Analysis and Commentary) 38 (2010): 386–91.
39. Robert Musil, A Man Without Qualities (New York: Alfred A. Knopf, 1995).
CHAPTER SIX
1. A. J. Frances, “A warning sign on the road to DSM-V: Beware of its unintended consequences,” Psychiatry Times 26, no. 8 (2009): 1–4.
2. A. Frances, “Opening Pandora’s Box: The Nineteen Worst Suggestions in DSM-5,” Psychiatric Times (March and April 2009): http://www.psychiatrictimes.com/print/article/10168/1522341.
3. Laura Batstra and Ernst Thoutenhoofd, “The Risk That DSM-5 Will Further Inflate the Diagnostic Bubble,” Current Psychiatry Reviews 8, no. 4 (November 2012): 260–63.
4. Joel Paris, MD, “The Risk That DSM-5 Will Give Personality Dimensions a Bad Name,” Current Psychiatry Reviews 8, no. 4 (November 2012): 268–70.
5. A. J. Frances, “Dimensional diagnosis of personality—not whether, but when and which,” Psychol Inq 4 (1993): 110–11.
6. Dayle K. Jones, PhD, “The Risk That DSM-5 Will Reduce the Credibility of Psychiatric Diagnosis,” Current Psychiatry Reviews 8, no. 4 (November 2012): 277–80.
7. A. Frances, “Whither DSM-5,” British Journal of Psychiatry 195, no. 5 (November 2009): 391–92.
8. A. Frances, “The First Draft of DSM-V,” British Journal of Psychiatry, March 2, 2010, http://www.bmj.com/content/340/bmj.c1168?tab=responses.
9. James Phillips, MD, and Allen Frances, MD, “The Seven Biggest Risks Posed by DSM-5,” Current Psychiatry Reviews 8, no. 4 (November 2012): 257–59.
10. Dayle K. Jones, “A Critique of the DSM-5 Field Trials,” Journal of Nervous & Mental Disease 200, no. 6 (June 2012): 517–19; doi: 10.1097/NMD.0b013e318257c699.
11. A. Frances, “Limitations of Field Trials,” American Journal of Psychiatry 166, no. 12 (December 2009): 1322.
12. Martin Whitely and Melissa Raven, PhD, “The Risk that DSM-5 Will Result in a Misallocation of Scarce Resources,” Current Psychiatry Reviews 8, no. 4 (November 2012): 281–86.
13. Gary Greenberg, PhD, “The Risk That DSM-5 Will Affect the Way We See Ourselves,” Current Psychiatry Reviews 8, no. 4 (November 2012): 287–89.
14. F. Leibenluft and others. “Chronic vs. episodic irritability in youth: A community-based, longitudinal study of clinical and diagnostic associations,” Journal of Child and Adolescent Psychopharmacology 16 (2006): 456–66.
15. S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerard, “Broadened use of atypical antipsychotics: Safety, effectiveness, and policy changes,” Health Affairs 28, no. 5 (2009): 770–81.
16. Bradley T. Hyman and others, “National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease,” Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 8, no. 1 (2012): 1–13.
17. L. M. Schwartz and S. Woloshin, “How the FDA forgot the evidence: the case of donepezil 23 mg,” BMJ 344 (2012): 1086.
18. Worst Pills, Best Pills, “Aricept,” Public Citizen, September 2012 (accessed September 5, 2012); https://www.worstpills.org/results.cfm?drug_id=217&x=34&y=6.
19. Ethical Issues in Diagnosing and Treating Alzheimer’s Disease; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990623.
20. J. I. Hudson, E. Hiripi, H. G. Pope Jr., and R. C. Kessler “The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication,” Biological Psychiatry 61, no. 3 (2007): 348–58.
21. Joanna Moncrief and Sami Timimi, “Critical analysis of the concept of adult attention-deficit hyperactivity disorder,” The Psychiatrist 35 (2011): 334–38; doi: 10.1192/pb.bp.110.033423.
22. A. G. Harrison, M. J. Edwards, and K. C. Parker, “Identifying students faking ADHD: Preliminary findings and strategies for detection,” Archives of Clinical Neuropsychology 22, no. 5 (2007): 577–88.
23. C. A. Quinn, “Detection of malingering in assessment of adult ADHD,” Archives of Clinical Neuropsychology 18, no. 4 (2003): 379–95.
24. B. K. Sullivan, K. May, and L. Galbally, “Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments,” Applied Neuropsychology 14, no. 3 (2007): 189–207.
25. Jerome C. Wakefield and Mark F. Schmitz, “Recurrence of Depression After Bereavement-Related Depression: Evidence for the Validity of DSM-IV Bereavement Exclusion from the Epidemiologic Cat
chment Area Study,” Journal of Nervous & Mental Disease 200, no. 6 (June 2012): 480–85; doi: 10.1097/NMD.0b013e318248213f.
26. “Living with Grief” (editorial) Lancet 379, no. 9816 (18 February 2012): 589. doi: 10.1016/S01406736(12)60248-7.
27. Arthur Kleinman, “Culture, Bereavement, and Psychiatry,” The Lancet 379, issue 9816 (February 18, 2012): 608–609, doi:10.1016/S0140-6736(12)60258-X.
28. Richard A. Friedman, MD, “Grief, Depression, and the DSM-5,” N Engl J Med 366 (May 17, 2012): 1855–57.
29. Joanne Cacciatore, “Blog Post Goes Viral: MISS Foundation + Over 75K Readers Denounce DSM-5 Changes to Bereavement Exclusion,” PR Web, posted March 6, 2012; http://www.prweb.com/releases/DSMV_EthicalRelativism/Cacciatore/prweb9258619.htm (accessed September 5, 2012).
30. Ron Mihordin, “Behavioral Addiction—Quo Vadis?” Journal of Nervous & Mental Disease 200, no. 6 (June 2012): 489–91; doi: 10.1097/NMD.0b013e318257c503.
31. R. Collier, “Internet addiction: New-age diagnosis or symptom of age-old problem?” Canadian Medical Association Journal 181, no. 9 (2009): 575–76.
32. Wikipedia. “Oniomania,” last modified Auguat 4, 2012; http://en.wikipedia.org/wiki/Oniomania.
33. Wikipedia. “Workaholic,” last modified August 22, 2012; http://en.wikipedia.org/wiki/Workaholism.
34. Wikipedia, “Exercise Addiction,” lasted modified June 29, 2012; http://en.wikipedia.org/wiki/Exercise_addiction.
35. Wikipedia, “Tanning Addiction,” last modified August 2, 2012; http://en.wikipedia.org/wiki/Tanning_addiction.
36. Jane Collingwood, “Does Chocolate Addiction Exist?” PsychCentral.com, http://psychcentral.com/lib/2006/does-chocolate-addiction-exist.
37. Alison Yung, MD, “Should attenuated psychosis syndrome be included in DSM-5?” The Lancet 379, issue 9816 (February 18, 2012): 591–92; doi:10.1016/S0140-6736(11)61507-9.
38. Peter J. Weiden, MD, “The Risk That DSM-5 Will Promote Even More Inappropriate Anti-psychotic Exposure in Children and Teenagers,” Current Psychiatry Reviews 8, no. 4 (November 2012): 271–76.
39. C. M. Corcoran, M. B. First, and B. Cornblatt, “The psychosis risk syndrome and its proposed inclusion in the DSM-V: A risk-benefit analysis,” Schizophr Res 120 (2010): 16–22.
40. Colin Ross “DSM-5 and the ‘Psychosis Risk Syndrome’: Eight reasons to reject it,” Psychosis: Psychological, Social and Integrative Approaches 2, no. 2 (2010): 107–10; http://www.tandfonline.com/doi/abs/10.1080/17522431003763323.
41. A. Jennex and D. M. Gardner, “Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study,” Can J Psychiatry 53 (2008): 4–42.
42. Neeltje M. Batelaan, Jan Spijker, Ron de Graaf, and Cuijpers, “Mixed Anxiety Depression Should Not Be Included in DSM-5,” Pim Journal of Nervous & Mental Disease 200, no. 6 (June 2012): 495–98; doi: 10.1097/NMD.0b013e318257c4c9.
43. K. Walters and others, “Mixed anxiety and depressive disorder outcomes: prospective cohort study in primary care,” Br J Psychiatry 198, no. 6 (June 2011): 472–78.
44. A. J. Frances, “The forensic risks of DSM-V and how to avoid them,” J Am Acad Psychiatry Law 38 (2010): 11–14.
45. P. Good and J. Burstein, “Hebephilia and the Construction of a Fictitious Diagnosis,” Journal of Nervous & Mental Disease 200, no. 6 (June 2012): 492–94; doi: 10.1097/NMD.0b013e318257c4f1.
46. Allen Frances, MD, “The Risk That DSM-5 Will Exacerbate the SVP Mess in Forensic Psychiatry,” Current Psychiatry Reviews 8, no. 4 (November 2012): 264–67.
47. A. J. Reid Finlayson, John Sealy, and Peter R. Martin, “Sexual Addiction and Compulsivity,” Journal of Treatment & Prevention 8, no. 3–4 (2001): 241–51; doi:10.1080/107201601753459946.
48. R. C. Kessler, K. R. Merikangas, P. Berglind, W. W. Eaton, D. S. Koretz, and E. E. Walters, “Mild disorders should not be eliminated from the DSM-5,” Arch Gen Psychiatry 60 (2003): 1117–22.
CHAPTER SEVEN
1. Mark Thornton, “Alcohol Prohibition Was a Failure,” Policy Analysis (1991); http://www.cato.org/publications/policy-analysis/alcohol-prohibition-was-failure.
2. “The Drug War Spreads Instability,” The Globe and Mail, April 26, 2012, last updated September 6, 2012, Editorial Section; http://www.theglobeandmail.com/commentary/the-drug-war-spreads-instability/article4104311.
3. Centers for Disease Control and Prevention, “Prescription Painkiller Overdoses at Epidemic Levels,”(2011); http://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html.
4. Global Commission on Drug Policy, “The War on Drugs and HIV/AIDS: How the Criminalization of Drug Use Fuels the Global Pandemic,” http://globalcommissionondrugs.org/wp-content/themes/gcdp_v1/pdf/GCDP_HIV-AIDS_2012_REFERENCE.pdf.
5. Melissa Raven, “Direct-to-Consumer Advertising: Healthy Education or Corporate Spin?” Healthy Skepticism International News (2004); http://www.healthyskepticism.org/global/news/int/hsin2004-09.
6. Lee Fang, “When a Congressman Becomes a Lobbyist, He Gets a 1,452 Percent Raise (on Average),” The Nation, March 24, 2012. http://www.thenation.com/article/166809/when-congressman-becomes-lobbyist-he-gets-1452-percent-raise-average#.
7. Marcia Angell, “The Truth About the Drug Companies,” New York Review of Books 51, no. 12 (2004): 52–58.
8. K. Abbasi and R. Smith, “No More Free Lunches,” BMJ 326, no. 7400 (2003): 1155.
9. A. Fugh-Berman and S. Ahari, “Following the Script: How Drug Reps Make Friends and Influence Doctors,” PLoS Med 4, no. 4 (2007), http://www.ncbi.nlm.nih.gov/pubmed/17455991.
10. “An Unhealthy Disregard,” Nat Med 16, no. 6 (2010): 609.
11. R. N. Moynihan, “Kissing Goodbye to Key Opinion Leaders,” Med J Aust 196, no. 11 (2012): 671.
12. John Kaplan, “The Cost of Doing Business? Pharmaceutical Company Fines,” Bioethics Today, August 2, 2012, http://www.amc.edu/bioethicsblog/post.cfm/the-cost-of-doing-business-pharmaceutical-company-fines.
13. B. Mintzes, “Should Patient Groups Accept Money from Drug Companies? No,” BMJ 334, no. 7600 (2007): 935.
14. B. Mintzes, “Disease Mongering in Drug Promotion: Do Governments Have a Regulatory Role?” PLoS Med 3, no. 4 (2006); http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030198.
15. A. J. Fyer and others, “Discontinuation of Alprazolam Treatment in Panic Patients,” Am J Psychiatry 144, no. 3 (1987): 303–308.
16. David Rosenfeld, “Jackson Case Highlights Medical Ethics,” Pacific Standard (2012) http://www.psmag.com/health/jackson-case-highlights-medical-ethics-3572/
17. L. Batstra and A. Frances, “Diagnostic Inflation: Causes and a Suggested Cure,” J Nerv Ment Dis 200, no. 6 (2012): 474–79.
18. J. S. Comer, M. Olfson, and R. Mojtabai, “National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996–2007,” J Am Acad Child Adolesc Psychiatry 49, no. 10 (2010): 1001–10.
19. E. R. Hajjar, A. C. Cafiero, and J. T. Hanlon, “Polypharmacy in Elderly Patients,” Am J Geriatr Pharmacother 5, no. 4 (2007): 345–51.
20. V. Barbour and others, “False Hopes, Unwarranted Fears: The Trouble with Medical News Stories,” PLoS Med 5, no. 5 (2008) http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050118,
CHAPTER EIGHT
1. A. Frances, Essentials of Psychiatric Diagnosis (New York: Guilford Press, 2013).
INDEX
The pagination of this electronic edition does not match the edition from which it was created. To locate a specific entry, please use your e-book reader’s search tools.
Abilify, 105, 234
abnormal:
definitions of, 3, 4, 5, 16–18
line between normal and, 8, 13
vs. harmony, 35
abnormal behavior, as threat to the tribe, 37
accountability, 219
Adam’s Story, obsessive-compulsive disorder, 276–77
addictions, 188–92
addictive dru
gs, 88, 92, 95, 216
ADHD:
adult, 184–86
Cleo’s Story, 271–73
false epidemic of, 26, 74, 75, 104, 141–44
Liz’s Story, 253–55
ADHD drugs, profitability of, xv
adult attention deficit disorder, xvii, 184–86
adult bipolar disorder:
false epidemic of, 75, 104, 139
Susan’s Story, 250–53
advertising:
profitability of, 164
provocative, 202
see also drug companies
Affordable Care Act, 112
Age of Taxonomy, 54
agoraphobia, Susan’s Story, 266–67
AIDS/HIV, 32–33
alcohol:
and dance manias, 120
impact on mental disorder, 81–82, 238
alienists, 60
Alzheimer’s dementia:
laboratory tests needed for, 11
risk of, 180–81
American Psychiatric Association (APA):
absence of accountability in, 219
conflict of interest in, 226
and DSM-5, xvii, 170, 175–76, 219, 224, 227
and DSM-I, 61
and DSM-III, 63, 218
and DSM-IV, 70, 71
removing from DSM sponsorship, 218–20
amyloid, 180
angels, 119
animism, 38
anthropology, “normal” concepts in, 13–15
antianxiety drugs, 105, 156, 234
antidepressants:
and antipsychotics, 107
and bipolar II, 151
easy-to-use, 87, 88
emergence of, 91
lethal overdoses of, 92
and major depressive disorder, 156
misuse of, 100–101
profitability of, xv, 104
side effects of, 92
tricyclic, 91–92
antipsychotics:
and antidepressants, 107
emergence of, 91
misuse of, 105–6
overprescription of, 89, 105, 234
profitability of, xv, 104
side effects of, 89, 105
and temper tantrums, 178–79
Saving Normal : An Insider's Revolt Against Out-of-control Psychiatric Diagnosis, Dsm-5, Big Pharma, and the Medicalization of Ordinary Life (9780062229274) Page 32
